# To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL

Source: https://onco.cc/trials/nct04661007/  
OnCo record `nct04661007` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Tafasitamab, Lenalidomide in diffuse large b-cell lymphoma, run by Incyte Biosciences Japan GK, active and no longer recruiting.

## Summary

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) is a phase 1/2 interventional study registered as NCT04661007 by Incyte Biosciences Japan GK, with 72 participants enrolled, started 2020-12-15 and due to reach its primary completion in 2025-07-01. Interventions recorded: tafasitamab, lenalidomide, parsaclisib, R-CHOP. Conditions listed: Non Hodgkins Lymphoma, Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04661007
- Phase: 1/2
- Setting: A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma
- Sponsor: Incyte Biosciences Japan GK
- Enrolled: 72

## Sources

- ClinicalTrials.gov NCT04661007: https://clinicaltrials.gov/study/NCT04661007

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Parsaclisib](https://onco.cc/drugs/parsaclisib/), [Tafasitamab](https://onco.cc/drugs/tafasitamab/)
- companies: [Incyte](https://onco.cc/companies/incyte/)

---
JSON: https://onco.cc/api/v1/entities/nct04661007.json